The Center for Biosimilars® recaps the top news for the week of September 17, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 17.
Number 5: Chinese researchers are reporting positive preclinical results for a proposed cetuximab biosimilar.
Number 4: Mylan and Fujifilm have revealed that they will launch their adalimumab biosimilar in the European Union on or after October 16.
Number 3: The European Medicines Agency has published new materials intended to educate European patients about biosimilars.
Number 2: The Senate has passed a bill that would eliminate pharmacy gag clauses and require biosimilar and biologics developers to report patent settlements to the Federal Trade Commission.
Number 1: The State of California is suing AbbVie for allegedly using kickbacks and a network of nurses to illegally boost sales of Humira.
Finally, last week, our e-newsletter asked whether you think that interchangeability is the appropriate benchmark for pharmacy-level substitution.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.